H
Harrow Health | Imprimis Pharmaceuticals
Ophthalmic-focused pharmaceutical compounding and drug commercialization services
About Harrow Health | Imprimis Pharmaceuticals
Harrow, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded ophthalmic pharmaceutical company headquartered in Nashville, Tennessee. Founded in 2011 by Mark L. Baum, a lawyer by training with a history in the pharmacy field, the company focuses exclusively on eyecare pharmaceuticals. Baum, who serves as Chairman and CEO, has a background that includes founding an HIV-focused pharmacy business in 1999 and has been a vocal advocate for drug pricing accessibility. The company's evolution includes a name change from Harrow Health, Inc. to Harrow, Inc. to reflect its dedicated focus on ophthalmology.
Harrow's business model is multifaceted, combining a core pharmaceutical compounding business, ImprimisRx, with a growing portfolio of FDA-approved branded drugs and a function as a biotech incubator. Through ImprimisRx, the company provides customized, compounded sterile and topical drug formulations directly to physicians and patients, addressing conditions like dry eye, glaucoma, infections, and inflammation. Revenue is generated from direct sales of these compounded medications and its expanding line of branded products. The company serves ophthalmologists, hospitals, and ambulatory surgical centers across the United States. Harrow has pursued a strategy of acquiring commercial rights to established, FDA-approved ophthalmic drugs from major pharmaceutical companies like Novartis, Santen, and Samsung Bioepis, significantly expanding its product portfolio. This strategy allows Harrow to leverage its existing commercial platform to market both its compounded formulations and newly acquired branded products.
The company's product portfolio is comprehensive, covering medications used in millions of annual ophthalmic surgeries and for treating chronic eye conditions. Key products include compounded formulations like Dropless Therapy®, branded drugs acquired from other companies such as ILEVRO®, MAXITROL®, and VEVYE®, and biosimilars for major retinal disease treatments. Harrow has also established subsidiaries and holds equity in companies like Melt Pharmaceuticals and Surface Ophthalmics, which originated within Harrow. This approach of acquiring late-stage or already approved assets is designed to minimize regulatory and commercial risks. The company operates its own production and distribution facilities and is licensed to operate in all 50 U.S. states.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2013
- Outcome tier
- Unicorn$1–10B valuation tier
News
Open roles
Harrow Health | Imprimis Pharmaceuticals in the Nashville ecosystem
The Harrow Health | Imprimis Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Life Sciences Alternative Funding
Oaktree Capital Management
Fifth Third
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Patents
45 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Harrow Health | Imprimis Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Harrow Health | Imprimis Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


